News

June 15, 2020June 15, 2020

Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says

News

An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or preventing ... Read more

June 8, 2020June 8, 2020

Merck to Launch Ontruzant, a Herceptin Biosimilar, in US

News

Ontruzant (trastuzumab-dttb), a biosimilar to Genentech‘s Herceptin (trastuzumab), will now be made available in the U.S. as a treatment for HER2-overexpressing breast cancers as well as for stomach cancers, according to a ... Read more

June 4, 2020June 4, 2020

Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases

News

Kisqali (ribociclib) combined with endocrine therapy prolongs the overall survival of women with HR-positive, HER2-negative, advanced or metastatic breast cancer with visceral metastases (in the soft internal organs), data from two ... Read more

May 28, 2020May 28, 2020

3 Levels of Care Recommended for Breast Cancer Patients During COVID-19 Pandemic

News

For breast cancer care during the COVID-19 pandemic, a panel of experts has recommended that patients be divided into one of three categories based on the severity of their condition ... Read more

May 21, 2020May 21, 2020

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

News

Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors responding to treatment with a new class ... Read more

May 14, 2020May 14, 2020

Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland

News

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Seattle Genetics‘ Tukysa, in combination with trastuzumab and Xeloda (capecitabine), for the treatment of patients with metastatic HER2-positive breast cancer. Tukysa is now approved for ... Read more

May 7, 2020May 14, 2020

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

News

Seattle Genetics’ Tukysa (tucatinib) can now be used in combination with trastuzumab and Xeloda (capecitabine) to treat people with metastatic or inoperable HER2-positive breast cancer following its approval by the ... Read more

April 30, 2020April 30, 2020

Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan

News

Enhertu (trastuzumab deruxtecan) has been approved in Japan to treat adults with HER2-positive inoperable or metastatic breast cancer that is resistant to chemotherapy, or those who cannot tolerate it. Enhertu is an ... Read more

April 28, 2020April 28, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

News, syndicated

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their ... Read more

April 23, 2020April 23, 2020

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

News

The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic disease. ... Read more